The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 696, Issue 1, 2010, Pages 41-47

  López Lázaro, Miguel ^a,b   Willmore, Elaine ^a   Austin, Caroline A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Cancer; Carcinogenesis; Topoisomerase poison

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; APIGENIN; CAMPTOTHECIN; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FISETIN; MYRICETIN; QUERCETIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOGENS; FLAVONOIDS; HUMANS; K562 CELLS; MICE; TOPOISOMERASE I INHIBITORS; TOPOISOMERASE II INHIBITORS;

MURINAE;

EID: 74649084195     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2009.12.010     Document Type: Article

References (41)

1. Ren W., Qiao Z., Wang H., Zhu L., and Zhang L. Flavonoids: promising anticancer agents. Med. Res. Rev. 23 (2003) 519-534
2. Lopez-Lazaro M. Flavonoids as anticancer agents: structure-activity relationship study. Curr. Med. Chem. Anticancer Agents 2 (2002) 691-714
3. Manach C., and Donovan J.L. Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic. Res. 38 (2004) 771-785
4. Li Y., Fang H., and Xu W. Recent advance in the research of flavonoids as anticancer agents. Mini Rev. Med. Chem. 7 (2007) 663-678
5. Ross J.A. Dietary flavonoids and the MLL gene: a pathway to infant leukemia?. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4411-4413
6. Strick R., Strissel P.L., Borgers S., Smith S.L., and Rowley J.D. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4790-4795
7. Galati G., and O'Brien P.J. Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic. Biol. Med. 37 (2004) 287-303
8. Rietjens I.M., Boersma M.G., van der W.H., Jeurissen S.M., Schutte M.E., and Alink G.M. Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. Mutat. Res. 574 (2005) 124-138
9. van Doorn-Khosrovani B.v.W., Janssen J., Maas L.M., Godschalk R.W., Nijhuis J.G., and van Schooten F.J. Dietary flavonoids induce MLL translocations in primary human CD34+ cells. Carcinogenesis 28 (2007) 1703-1709
10. Champoux J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70 (2001) 369-413
11. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 3 (2002) 430-440
12. Fortune J.M., and Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol. 64 (2000) 221-253
13. Sordet O., Khan Q.A., Kohn K.W., and Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anticancer Agents 3 (2003) 271-290
14. Austin C.A., Patel S., Ono K., Nakane H., and Fisher L.M. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem. J. 282 (1992) 883-889
15. Constantinou A., Mehta R., Runyan C., Rao K., Vaughan A., and Moon R. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J. Nat. Prod. 58 (1995) 217-225
16. Boege F., Straub T., Kehr A., Boesenberg C., Christiansen K., Andersen A., Jakob F., and Kohrle J. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J. Biol. Chem. 271 (1996) 2262-2270
17. Cho K.H., Pezzuto J.M., Bolton J.L., Steele V.E., Kelloff G.J., Lee S.K., and Constantinou A. Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. Eur. J. Cancer 36 (2000) 2146-2156
18. Lopez-Lazaro M., Martin-Cordero C., and Ayuso M.J. Two new flavonol glycosides as DNA topoisomerase I poisons. Z. Naturforsch. [C] 55 (2000) 898-902
19. Lopez-Lazaro M., Martin-Cordero C., Toro M.V., and Ayuso M.J. Flavonoids as DNA topoisomerase I poisons. J. Enzyme Inhib. Med. Chem. 17 (2002) 25-29
20. Chowdhury A.R., Sharma S., Mandal S., Goswami A., Mukhopadhyay S., and Majumder H.K. Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem. J. 366 (2002) 653-661
21. Webb M.R., and Ebeler S.E. Comparative analysis of topoisomerase IB inhibition and DNA intercalation by flavonoids and similar compounds: structural determinates of activity. Biochem. J. 384 (2004) 527-541
22. Bandele O.J., and Osheroff N. Bioflavonoids as poisons of human topoisomerase IIalpha and IIbeta. Biochemistry 46 (2007) 6097-6108
23. Felix C.A. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med. Pediatr. Oncol. 36 (2001) 525-535
24. Felix C.A. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta 1400 (1998) 233-255
25. Mistry A.R., Felix C.A., Whitmarsh R.J., Mason A., Reiter A., Cassinat B., Parry A., Walz C., Wiemels J.L., Segal M.R., Ades L., Blair I.A., Osheroff N., Peniket A.J., Lafage-Pochitaloff M., Cross N.C., Chomienne C., Solomon E., Fenaux P., and Grimwade D. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N. Engl. J. Med. 352 (2005) 1529-1538
26. Hofland K.F., Thougaard A.V., Sehested M., and Jensen P.B. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin. Cancer Res. 11 (2005) 3915-3924
27. Cantero G., Campanella C., Mateos S., and Cortes F. Topoisomerase II inhibition and high yield of endoreduplication induced by the flavonoids luteolin and quercetin. Mutagenesis 21 (2006) 321-325
28. Pastor N., Cantero G., Campanella C., and Cortes F. Endoreduplication induced in cultured Chinese hamster cells by different anti-topoisomerase II chemicals. Evidence for the essential contribution of the enzyme to chromosome segregation. Mutat. Res. 582 (2005) 11-19
29. Errington F., Willmore E., Tilby M.J., Li L., Li G., Li W., Baguley B.C., and Austin C.A. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol. Pharmacol. 56 (1999) 1309-1316
30. Cowell I.G., Willmore E., Chalton D., Marsh K.L., Jazrawi E., Fisher L.M., and Austin C.A. Nuclear distribution of human DNA topoisomerase IIbeta: a nuclear targeting signal resides in the 116-residue C-terminal tail. Exp. Cell Res. 243 (1998) 232-240
31. Willmore E., Frank A.J., Padget K., Tilby M.J., and Austin C.A. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol. Pharmacol. 54 (1998) 78-85
32. Padget K., Carr R., Pearson A.D., Tilby M.J., and Austin C.A. Camptothecin-stabilised topoisomerase I-DNA complexes in leukemia cells visualised and quantified in situ by the TARDIS assay (trapped in agarose DNA immunostaining). Biochem. Pharmacol. 59 (2000) 629-638
33. Willmore E., Errington F., Tilby M.J., and Austin C.A. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukemia cells. Biochem. Pharmacol. 63 (2002) 1807-1815
34. Lopez-Lazaro M., Willmore E., and Austin C.A. Cells lacking DNA topoisomerase IIbeta are resistant to genistein. J. Nat. Prod. 70 (2007) 763-767
35. Austin C.A., Marsh K.L., Wasserman R.A., Willmore E., Sayer P.J., Wang J.C., and Fisher L.M. Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta. J. Biol. Chem. 270 (1995) 15739-15746
36. Snyder R.D., and Gillies P.J. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells. Environ. Mol. Mutagen. 40 (2002) 266-276
37. Olaharski A.J., Mondrala S.T., and Eastmond D.A. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin. Mutat. Res. 582 (2005) 79-86
38. Snyder R.D., and Gillies P.J. Reduction of genistein clastogenicity in Chinese hamster V79 cells by daidzein and other flavonoids. Food Chem. Toxicol. 41 (2003) 1291-1298
39. Hartmann J.T., and Lipp H.P. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II-mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf. 29 (2006) 209-230
40. Aisner J., Musanti R., Beers S., Smith S., Locsin S., and Rubin E.H. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based phase I trial. Clin. Cancer Res. 9 (2003) 2504-2509
41. Lopez-Lazaro M., Willmore E., Jobson A., Gilroy K.L., Curtis H., Padget K., and Austin C.A. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. J. Nat. Prod. 70 (2007) 1884-1888